Skip to Content

Tocilizumab Use Not Supported for Moderate-to-Severe COVID-19

THURSDAY, March 11, 2021 -- Tocilizumab is not associated with progression of COVID-19 among adults admitted to hospital with moderate-to-severe COVID-19, according to a study published online March 4 in The Lancet Respiratory Medicine.

Arvinder S. Soin, from The Medicity Hospital in Gurugram, India, and colleagues conducted a multicenter, randomized, controlled phase 3 trial at 12 hospitals across India to examine whether tocilizumab could prevent COVID-19 progression. One hundred eighty adults admitted to hospital with moderate-to-severe COVID-19 were recruited between May 30, 2020, and Aug. 31, 2020, and were randomly assigned to receive either tocilizumab plus standard care or standard care alone (90 to each group). One patient randomly assigned to the standard care group inadvertently received tocilizumab.

The researchers found that progression of COVID-19 up to day 14 occurred in 9 and 13 percent of patients in the tocilizumab and standard care groups, respectively (difference, −3.71 percent; 95 percent confidence interval, −18.23 to 11.19 percent; P = 0.42). Adverse events occurred in 36 and 25 percent of patients in the tocilizumab and standard care groups, respectively, and serious adverse events occurred in 20 and 17 percent, respectively. Acute respiratory distress syndrome was the most common adverse event and was reported in 8 percent of patients in each group. Overall, 14 and 17 percent of patients in the tocilizumab and standard care groups, respectively, died during the study.

"Our study does not support the routine use of tocilizumab in adults with COVID-19," the authors write. "However, there might be a role for it in patients with severe COVID-19 that should be defined further."

One author disclosed financial ties to Roche; the study was partially funded and investigational medicinal product was supplied by Cipla and Roche India.

Abstract/Full Text

© 2021 HealthDay. All rights reserved.

Read this next

Risk for Subsequent SARS-CoV-2 Infection Lower With Seropositivity

MONDAY, April 19, 2021 -- Among healthy, young adults, those who are seropositive rather than seronegative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have a...

Half of American Adults Have Received at Least One COVID-19 Vaccine Shot

MONDAY, April 19, 2021 -- Half of all Americans aged 18 years or older have now gotten at least one shot in the arm of a COVID-19 vaccine, the U.S. Centers for Disease Control and...

AAN: Stroke Occurs in 2.2 Percent of Patients Admitted to ICU With COVID-19

MONDAY, April 19, 2021 -- For patients with COVID-19 admitted to the intensive care unit (ICU), stroke is not a common complication, according to a study presented at the annual...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.